{"id":4960,"date":"2016-05-17T12:32:40","date_gmt":"2016-05-17T12:32:40","guid":{"rendered":"http:\/\/congressmed.com\/cobrca\/?page_id=4960"},"modified":"2025-04-01T12:20:49","modified_gmt":"2025-04-01T12:20:49","slug":"industry-symposia","status":"publish","type":"page","link":"https:\/\/cobrca.org\/cobrca2024\/industry-symposia\/","title":{"rendered":"Industry Symposia"},"content":{"rendered":"

Industry Symposia<\/strong><\/h3>\n
\n

These sessions do not form part of the CME program.<\/p>\n

In line with current regulations, medical students, patient advocates and patients will not be allowed access to the exhibition area or pharma supported symposia.<\/p>\n

Wednesday, September 11, 2024<\/strong><\/span><\/p>\n\n\n\n
12:00-13:00
\nHall A<\/span><\/strong><\/td>\n		Industry Lunch Symposium: Treatment approaches to high risk early breast cancer<\/a>
\n<\/strong>Lilly sponsored symposium. Lilly products will be discussed at this symposium<\/span><\/em>
\n<\/span><\/strong><\/strong>*Lunch boxes will be served to session participants prior to the session\u00a0<\/em><\/span><\/td>\n		\"Lilly\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Thursday, September 12, 2024<\/strong><\/span><\/p>\n\n\n\n\n\n\n
07:30-08:30
\nHall A<\/span><\/strong><\/td>\n		Breakfast Industry Symposium: What is the true utility of genomic testing in Early Breast Cancer? A closer look at intrinsic subtyping and Prosigna<\/a>
\nSupported by Veracyte<\/em><\/span><\/strong><\/strong>
\n*Light refreshments will be served prior to the session at 07:00<\/em><\/span><\/td>\n		\"\"<\/td>\n<\/tr>\n
07:30-08:30
\nHall B<\/span><\/strong><\/td>\n		Breakfast Industry Symposium: Sharing clinical experience with eligible women with HR+\/HER2- advanced breast cancer \u2013 interactive case studies and panel discussions<\/a>
\n<\/strong><\/strong><\/strong>This promotional symposium has been organised and funded by Novartis Pharmaceuticals UK Ltd.<\/strong>
\nNovartis products will be discussed at this symposium and prescribing information will be available from a Novartis representative during the symposium<\/strong>
\nUK I August 2024 I FA-11253802<\/strong>
\n<\/span><\/em>*Light refreshments will be served prior to the session at 07:00<\/em><\/td>\n		\"\"<\/td>\n<\/tr>\n
12:30-13:30
\nHall A<\/span><\/strong><\/td>\n		Pre-Lunch Industry Symposium: Push the paradigm: Advances in treating HER2-expressing metastatic breast cancer<\/strong><\/a>
\n<\/span><\/strong><\/strong>Sponsored by Daiichi Sankyo UK and AstraZeneca UK. This is a promotional symposium organised and funded by Daiichi Sankyo UK and AstraZeneca UK, at which Daiichi Sankyo and AstraZeneca products will be discussed within their UK Marketing Authorisations.
\n<\/em>UK\/ADC\/07\/24\/0032 | July 2024<\/td>\n		\"\"<\/td>\n<\/tr>\n
12:30-13:30
\nHall B<\/span><\/strong><\/td>\n		Pre-Lunch Industry Symposium: Clinical utility of the 7-gene predictive DCIS test to accurately stratify risk and predict radiation benefit vs. clinicopathologic tools alone<\/a>
\n<\/strong>Supported by PreludeDx<\/span><\/strong><\/strong><\/em><\/td>\n		\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Friday, September 13, 2024<\/strong><\/span><\/p>\n\n\n\n
07:30-08:30<\/span><\/strong>
\nHall B<\/span><\/strong><\/td>\n		Breakfast Industry Symposium: <\/strong><\/strong>The Great Axillary Debates:<\/em> How do you surgically de-escalate<\/strong><\/a>
\nSupported by Endomag
\n<\/em><\/span><\/strong><\/strong>*Light refreshments will be served prior to the session at 07:00<\/span><\/em><\/td>\n		\"endomag\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Industry Symposia These sessions do not form part of the CME program. In line with current regulations, medical students, patient advocates and patients will not be [\u2026]<\/span><\/p>\n","protected":false},"author":12,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4960","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/4960"}],"collection":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/comments?post=4960"}],"version-history":[{"count":154,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/4960\/revisions"}],"predecessor-version":[{"id":10378,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/4960\/revisions\/10378"}],"wp:attachment":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/media?parent=4960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}